Italia markets closed

DBV Technologies S.A. (0QAJ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
4,7347+0,0967 (+2,08%)
Alla chiusura: 06:19PM BST

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette
Montrouge 92120
33 1 55 42 78 78

Impiegati a tempo pieno105


DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Governance aziendale

L'ISS Governance QualityScore di DBV Technologies S.A. al 1 giugno 2024 è 10. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.